Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT00167310
Show Display Options
Rank Status Study
1 Completed Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
Conditions: Schizophrenia;   Schizoaffective Disorder;   Major Depression;   Bipolar Disorder;   Coronary Artery Disease
Interventions: Drug: Eicosapentaenoic acid (omega-3 fatty acid);   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.